Hirotaka Horiguchi

Hirosaki, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Efficacy, Safety, and Cost-Effectiveness of Reduced versus Full Initial Doses of Androgen Receptor Signaling Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Study.

Efficacy, Safety, and Cost-Effectiveness of Reduced versus Full Initial Doses of Androgen Receptor Signaling Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Study.

Journal: The Prostate

Published: December 31, 2025

Cross-resistance among novel androgen receptor signaling inhibitors in non-metastatic castration-resistant prostate cancer.

Cross-resistance among novel androgen receptor signaling inhibitors in non-metastatic castration-resistant prostate cancer.

Journal: International journal of clinical oncology

Published: June 20, 2025

Real-world trends in the use and outcomes of novel androgen receptor signaling inhibitor therapy in patients with non-metastatic castration-resistant prostate cancer: a multicenter retrospective study.

Real-world trends in the use and outcomes of novel androgen receptor signaling inhibitor therapy in patients with non-metastatic castration-resistant prostate cancer: a multicenter retrospective study.

Journal: International journal of clinical oncology

Published: April 13, 2025

Impact of Skin Adverse Events on Prognosis in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin: A Real-World Multicenter Study.

Impact of Skin Adverse Events on Prognosis in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin: A Real-World Multicenter Study.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: October 30, 2024

Treatment trends in patients with de novo metastatic prostate cancer in the era of upfront combination therapy.

Treatment trends in patients with de novo metastatic prostate cancer in the era of upfront combination therapy.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: March 13, 2024

Combination of Muscle Quantity and Quality Is Useful to Assess the Necessity of Surveillance after a 5-Year Cancer-Free Period in Patients Who Undergo Radical Cystectomy: A Multi-Institutional Retrospective Study.

Combination of Muscle Quantity and Quality Is Useful to Assess the Necessity of Surveillance after a 5-Year Cancer-Free Period in Patients Who Undergo Radical Cystectomy: A Multi-Institutional Retrospective Study.

Journal: Cancers

Published: December 14, 2022

Utility of the Age Discrepancy between Frailty-Based Biological Age and Expected Life Age in Patients with Urological Cancers.

Utility of the Age Discrepancy between Frailty-Based Biological Age and Expected Life Age in Patients with Urological Cancers.

Journal: Cancers

Published: November 23, 2022

Trends in the age of hospitalized patients with urological cancers: A 17-year experience.

Trends in the age of hospitalized patients with urological cancers: A 17-year experience.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: November 21, 2022

Oncological and functional outcomes of female reproductive organ-sparing radical cystectomy and ileal neobladder construction.

Oncological and functional outcomes of female reproductive organ-sparing radical cystectomy and ileal neobladder construction.

Journal: Urologic oncology

Published: May 29, 2022

Significance of pelvic lymph node dissection during radical prostatectomy in high-risk prostate cancer patients receiving neoadjuvant chemohormonal therapy.

Significance of pelvic lymph node dissection during radical prostatectomy in high-risk prostate cancer patients receiving neoadjuvant chemohormonal therapy.

Journal: Scientific reports

Published: December 11, 2021

Prognostic impact of eligibility for adjuvant immunotherapy in locally advanced urothelial cancer.

Prognostic impact of eligibility for adjuvant immunotherapy in locally advanced urothelial cancer.

Journal: BJUI compass

Published: June 01, 2021

The impact of eligibility for maintenance immunotherapy on prognosis in patients with unresectable or metastatic urothelial carcinoma.

The impact of eligibility for maintenance immunotherapy on prognosis in patients with unresectable or metastatic urothelial carcinoma.

Journal: BJUI compass

Published: May 27, 2021

Showing 1-12 of 21

Last Updated: 09/26/2026